Welcome to UCB in Canada

Media & Funding

Media & Funding

Welcome to UCB's media room. This section offers resources for journalists, editors and other media professionals.

Blog

Building Awareness and Hope for Patients with HS: A conversation with Dr. Hélène Veillette
LEARN MORE
Accelerating the Diagnosis of axSpA in Canada: How FASTRAX is Reshaping the Patient Journey
LEARN MORE

Latest News

CDA-AMC draft recommendation for PrBIMZELX®

UCB Canada remains dedicated to helping patients and working collaboratively with CDA-AMC following draft recommendation for PrBIMZELX® for hidradenitis suppurativa (HS)

LEARN MORE
PrBIMZELX®

Now Approved in Canada for the Treatment of Moderate to Severe Hidradenitis Suppurativa (HS)

LEARN MORE
UCB Canada Expands FASTRAX to Thunder Bay

Enhancing Axial Spondyloarthritis (axSpA) Patient Care in Northern Ontario

LEARN MORE
Enhanced Access to gMG Treatments:

UCB Canada Secures pCPA Agreements for ZILBRYSQ® and RYSTIGGO®

LEARN MORE
PrRYSTIGGO®

Now Approved for Adults with Generalized Myasthenia Gravis (gMG) in Canada

LEARN MORE
02/03/2024
ZILBRYSQ® (zilucoplan injection)

Now Approved for Adults with Generalized Myasthenia Gravis (gMG) in Canada

LEARN MORE

Media Relations for UCB Canada

If you are a member of the media and require further information about UCB Canada Inc. or its products, please contact: mediacanada@ucb.com.